Predictive Biomedicine and Translational Research in Respiratory, Cardiovascular, and Metabolic Diseases

Strategic objectives

  • To encourage and facilitate basic-clinical translational research in respiratory, cardiovascular, and metabolic diseases.
  • To identify biomarkers and clinical predictors related to the prevention, prognosis, and treatment efficacy of respiratory, cardiovascular, and metabolic diseases.
  • To study the efficacy of new drugs in respiratory, cardiovascular, and metabolic diseases. To identify biomarkers and molecular signalling pathways related to drug response in cells.
  • To promote quality care and innovation in the clinical management of respiratory, cardiovascular, and metabolic diseases.
  • To promote the creation of national registers of rare respiratory diseases.
  • To study genes and genetic polymorphisms associated with nutrition and physical exercise potentially related to the risk of respiratory, cardiovascular, and metabolic diseases.
  • To study mechanisms associated with cellular senescence.
  • One of the main strategic objectives of the group is also training and teaching through doctoral theses and the publication of scientific and informative books.

Lines of research

  • Development of predictive algorithms using artificial intelligence based on genetic and protein biomarkers that predict overweight/obesity, comorbidities and ageing.
  • Search for biomarkers and clinical predictors of prognosis and/or adherence to secondary and tertiary prevention systems for cardiovascular, respiratory and metabolic diseases based on secondary sources.
  • Study of molecular mechanisms associated with the development and progression of abdominal aortic aneurysm and varicose veins and the action of drugs.
  • Mechanisms related to pathological alterations of the auditory system.
  • Analysis of the mechanisms associated with the response of platelets and their surrounding cells to antithrombotic and anticoagulant treatments. COVID-19 effects on the vascular wall.
  • Study of biomarkers modifying alpha-1 antitrypsin deficiency.
  • Development of a non-invasive intelligent medical device for the treatment of sleep apnoea syndrome.
  • Evaluative analysis of quality standards in chronic obstructive pulmonary disease care.
  • Study of clinical predictors to establish lifestyle changes in chronic obstructive pulmonary disease.
  • Study of the effectiveness of inhaled antibiotic treatment in chronic obstructive pulmonary disease.
  • Study of the impact of inhalers on respiratory health and the environment.
  • Prediction of cancer in COPD
  • Prediction of cardiovascular risk in COPD
  • Prediction of liver disease by polymorphisms in alpha 1-antitrypsin deficiency
  • Prediction of functional loss of emphysema by alpha 1-antitrypsin deficiency

Publications

Projects